Table 1.
Baseline demographic, clinical characteristics and vaccines received.
| IR (n= 22) | DIR (n= 24) | p | |
|---|---|---|---|
| Male sex, n (%) | 20 (90.9) | 16 (66.7) | 0.074 |
| Age, years | 48 (42–53) | 56 (47–60) | 0.060 |
| Risk for HIV infection, n (%) | |||
| MSM | 13 (59.1) | 7 (29.2) | 0.220 |
| HTX | 5 (22.7) | 8 (33.30) | |
| Previous iv drug use | 3 (13.6) | 6 (25.0) | |
| Others | 1 (4.5) | 3 (12.5) | |
| CD4+ T cell count, cells/μL | 654 (512–849) | 168 (106–208) | < 0.001 |
| CD4+/CD8+ ratio | 1.12 (0.85–1.50) | 0.30 (0.15–0.53) | < 0.001 |
| Nadir CD4+ T cells/μl | 258 (138–301) | 47 (27–84) | < 0.001 |
| Highest HIV-RNA, log10 copies/ml | 4.95 (2.25–5.74) | 5.37 (4.58–5.73) | 0.391 |
| Months on treatment | 151 (79–171) | 146 (45–218) | 0.956 |
| HIV-RNA <50 copies/ml, months | 129 (71–153) | 141 (41–201) | 0.749 |
| AIDS-defining illness, n (%) | 4 (18.2) | 9 (37.5) | 0.197 |
| Comorbidities, n (%) | 0.706 | ||
| Diabetes mellitus | 1 (4.0) | 3 (13.6) | |
| Liver cirrhosis with portal hypertension | − | 2 (8.0) | |
| Chronic portal cavernomatosis with portal hypertension | − | 1 (4.0) | |
| Visceral leishmaniasis (on treatment > 6 moths) | − | 1 (4.0) | |
| Antiretroviral treatment, n (%) | 0.343 | ||
| InSTI + 2 NRTI | 5 (22.7) | 9 (37.5) | |
| InSTI + 1 NRTI | 6 (27.3) | 8 (33.3) | |
| NNRTI + 1 NRTI | 2 (9.1) | 2 (8.3) | |
| bPI + 1 NRTI | 9 (40.9) | 2 (8.3) | |
| InSTI + bPI | 2 (8.3) | ||
| InstI + NNRTI | 1 (4.2) | ||
| mRNA-1273/BNT162b2 (1st - 2nd dose), n (%) | 4/18 (18.2/81.8%) | 19/5 (79.2/20.8%) | < 0.001 |
| mRNA-1273/BNT162b2 (3rd dose), n (%) | 1/9 (10/90%) | 10/6 (62.5/37.5) | 0.011 |
IR, immunological responders; DIR, discordant immune responders; MSM, men who have sex with men; HTX, heterosexual; InSTI, integrase strand transfer inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitors; bPI, boosted protease inhibitor.